Gynecologic cancerNew technologies in cervical cancer precursor detectionSoler, Maria Elena MD, MPH; Blumenthal, Paul D. MD, MPHAuthor Information Department of Obstetrics/Gynecology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA Correspondence to Paul D. Blumenthal, MD, MPH, Department of Obstetrics/Gynecology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave., Room 125, Baltimore, MD 21224, USA; e-mail: email@example.com Current Opinion in Oncology: September 2000 - Volume 12 - Issue 5 - p 460-465 Buy Abstract The current literature reflects three routes toward improving cervical cancer screening. The first is to improve the test qualities of cytology-based screening. The use of liquid-based cytology and computerized analysis of Papanicolaou tests are examples of attempts at this approach. Secondly, through various combinations of parallel or sequential tests, either the sensitivity or the specificity of a given test could be improved depending on the tests chosen and the order in which they were performed (eg, Papanicolaou test followed by human papillomavirus [HPV] or vice versa). Several excellent studies have been published this year on the use of HPV DNA testing as a primary screening modality and as an adjunct to the triage of mildly abnormal cytologic findings. The recent literature also reflects increasing interest in visual inspection of the cervix and self-collected samples for HPV testing as an equally effective and viable alternative to cytology in low-resource settings. A third possibility is to make use of advances in digital and spectroscopic techniques. In these cost-conscious times, a significant number of articles address the cost-effectiveness of these technologies and the real value of cervical cancer screening. This article reviews the current literature concerning both the advent of new cervical cancer screening technologies and the rediscovery of old ones. © 2000 Lippincott Williams & Wilkins, Inc.